Table 6.
Author | Year | Cancer Type | circRNA | Expression in Tumour Tissue | Ass Association with Features of Malignancy Evaluated |
---|---|---|---|---|---|
Xu Y et al. [98] | 2018 | CCA | hsa_circ_0001649 | Down | In vitro, in vivo and clinical data |
Jiang X et al. [96] | 2018 | CCA | ciRS-7 (Cdr1as) | Up | Clinical data |
Kai D et al. [26] | 2018 | GBC | hsa_circ_0000284 (or circHIPK3) |
Up | In vitro |
Xu Y et al. [97] | 2019 | CCA | circ_0005230 | Up | In vitro, in vivo and clinical data |
Wang et al. [53] | 2019 | GBC | hsa_circ_0008234 (or circFOXP1) |
Up | In vitro, in vivo and clinical data |
Lu Q and Fang T [103] | 2019 | CCA | circSMARCA5 | Down | In vitro and clinical data |
Huang X et al. [33] | 2019 | GBC | circERBB2 | Up | In vitro, in vivo and clinical data |
Wang S et al. [100] | 2019 | CCA | hsa_circ_0000284 | Up | In vitro and in vivo |
Li D et al. [99] | 2020 | CCA | ciRS-7 (Cdr1as) | Up | In vitro and in vivo |
Xu Y et al. [101] | 2020 | CCA | hsa_circ_102064 (or circ-CCAC1) | Up | In vitro, in vivo and clinical data |